Topical benzyl alcohol reduces cataract surgery need: two long-term double blind studies.
Substances derived from biotransformation of non-steroid antiinflammatory drugs (NSAID) produced by patients responsive to the biological liquid oxidant activity (BLOA) test, have been shown to have anticataract activity. They are all aromatic alcohols with physico-chemical properties similar to benzyl alcohols (BA); they were very efficacious in preventing in vitro (cyanate, heat) cataracts and in vivo (uveitis, radiation, selenite) cataracts but had no effect on sugar cataracts. The mechanism underlying this effect seems to be mainly antioxidant together with a stabilizing effect on lens membrane integrity and a stimulating effect on Na-K ATPase and membrane sodium pump. The well balanced lipo- and hydro-solubility of these compounds makes them very suitable for topical application to the eye as lipid solubility is the major factor governing transcorneal penetration of drugs. In the two long-term double blind studies on humans described here, comparing BA, placebo and Catalin in the topical treatment of progressive cataract rapid (2-3 weeks treatment) reversal of incipient cataract was obtained accompanied by a marked improvement of vision and by a significantly lower percentage of eyes requiring surgery after 22 months treatment with BA than with placebo and Catalin. In conclusion, further studies on the effect on the eye of BA and similar compounds such as phenyl-ethanol are advisable especially because they are already used as preservatives in eye-drop formulations.
Testa
M
M
Department of Ophthalmology, University School of Medicine, Napoli, Italy.
Iuliano
G
G
Morton
P
P
Longoni
A
A
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D019905:Benzyl Alcohol; D001592:Benzyl Alcohols / Q000009:adverse effects / Q000627:therapeutic use*; D001593:Benzyl Compounds / Q000627:therapeutic use*; D002386:Cataract / Q000188:drug therapy*; D002387:Cataract Extraction; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000009:adverse effects / Q000627:therapeutic use
D001592:Benzyl Alcohols; D001593:Benzyl Compounds; D010078:Oxazines; C004580:pirenoxine; D019905:Benzyl Alcohol